Coeptis Therapeutics, Inc. (OTC PINK: COEP), along with its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (together “Coeptis”), is a biopharmaceutical company founded in 2017 and headquartered in Wexford, PA. Coeptis began with the intent to develop and commercialize generic and branded pharmaceutical products. After developing and divesting a portfolio of therapeutic products, Coeptis evolved into a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.